Breaking news

Pain symposium contribution

Our CSO Prof David Kendall is co-organizer of a British Pharmacological Society-sponsored symposium at the 2018 ELRIG Drug Discovery meeting in London in October (Read here). The symposium entitled “The opioid crisis, addiction and the search for more effective analgesics”, will bring together industrial and academic pain research experts and Prof Kendall will give a presentation on the potential of delta opioid receptor agonists in chronic pain therapy.

Read more →

PN6047 and respiratory depression

Since 2008 PharmNovo has developed novel molecules which are highly selective, potent and effective in animal models of chronic pain. We have designed compounds with ligand bias which means that they have a very favourable activity profile with none of the unwanted effects characteristic of conventional opioids that act mainly through mu opioid receptors. Our compounds are agonists of the delta opioid receptor, activation of which is known to effectively combat chronic but not acute pain.

Read more →

Find us

PharmNovo AB
Medicon Village AB
Scheelevägen 6
SE-223 81 Lund, Sweden